$48 Million is the total value of Versant Venture Management, LLC's 7 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | $22,549,778 | +11.3% | 498,558 | 0.0% | 47.01% | +12.1% | |
| GRTS | Gritstone Oncology, Inc. | $9,899,997 | -19.4% | 3,561,150 | 0.0% | 20.64% | -18.8% | |
| PASG | Passage Bio, Inc. | $4,749,971 | -30.6% | 4,959,769 | 0.0% | 9.90% | -30.1% | |
| CBAY | CymaBay Therapeutics, Inc. | $4,741,526 | +39.1% | 543,753 | 0.0% | 9.88% | +40.1% | |
| ADVM | Adverum Biotechnologies, Inc. | $3,635,950 | +23.8% | 5,068,233 | 0.0% | 7.58% | +24.7% | |
| ALGS | Aligos Therapeutics, Inc. | $2,028,013 | -8.3% | 2,320,381 | 0.0% | 4.23% | -7.6% | |
| Minerva Surgical Inc. | $367,377 | -1.7% | 1,673,700 | 0.0% | 0.77% | -1.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-11 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.